Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
32
ONCY Quote, Financials, Valuation and Earnings
Last price:
$0.98
Seasonality move
:
-1.52%
Day range:
$0.97 - $1.00
52-week range:
$0.33 - $1.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1,259.09x
Volume:
151K
Avg. volume:
647K
1-year change:
--
Market cap:
$104.4M
Revenue:
--
EPS (TTM):
-$0.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -13.85% | $5.55 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $5.33 |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -- | -- | -- | $105.58 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.16 | -- | -43.57% | $55.40 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ONCY
Oncolytics Biotech, Inc.
|
$0.97 | $5.55 | $104.4M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$16.29 | $16.67 | $2.1B | 29.03x | $0.00 | 0% | 8.65x |
|
EDSA
Edesa Biotech, Inc.
|
$1.30 | $11.00 | $9.1M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.56 | $5.33 | $13.9M | -- | $0.00 | 0% | 14.29x |
|
PMN
ProMIS Neurosciences, Inc.
|
$8.27 | $105.58 | $17.8M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$45.01 | $55.40 | $3.5B | -- | $0.00 | 0% | 473.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -0.093 | -- | 1.26x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
PMN
ProMIS Neurosciences, Inc.
|
-- | -$11.8M | -348.3% | -348.3% | -- | -$10.2M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
Oncolytics Biotech, Inc. vs. Competitors
-
Which has Higher Returns ONCY or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of 42.95%. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About ONCY or AUPH?
Oncolytics Biotech, Inc. has a consensus price target of $5.55, signalling upside risk potential of 472.27%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 2.82%. Given that Oncolytics Biotech, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ONCYOncolytics Biotech, Inc.3 1 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is ONCY or AUPH More Risky?
Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock ONCY or AUPH?
Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONCY or AUPH?
Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Oncolytics Biotech, Inc.'s net income of -$10.5M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 29.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 8.65x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M AUPHAurinia Pharmaceuticals, Inc.8.65x 29.03x $73.5M $31.6M
-
Which has Higher Returns ONCY or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of --. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About ONCY or EDSA?
Oncolytics Biotech, Inc. has a consensus price target of $5.55, signalling upside risk potential of 472.27%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ONCYOncolytics Biotech, Inc.3 1 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is ONCY or EDSA More Risky?
Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock ONCY or EDSA?
Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONCY or EDSA?
Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Oncolytics Biotech, Inc.'s net income of -$10.5M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns ONCY or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of -2178.51%. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About ONCY or LEXX?
Oncolytics Biotech, Inc. has a consensus price target of $5.55, signalling upside risk potential of 472.27%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $5.33 which suggests that it could grow by 852.38%. Given that Lexaria Bioscience Corp. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ONCYOncolytics Biotech, Inc.3 1 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is ONCY or LEXX More Risky?
Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock ONCY or LEXX?
Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONCY or LEXX?
Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Oncolytics Biotech, Inc.'s net income of -$10.5M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M LEXXLexaria Bioscience Corp.14.29x -- $174K -$2.7M
-
Which has Higher Returns ONCY or PMN?
ProMIS Neurosciences, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of --. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.
Company Gross Margin Earnings Per Share Invested Capital ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K PMNProMIS Neurosciences, Inc.-- -$5.93 $9.2M -
What do Analysts Say About ONCY or PMN?
Oncolytics Biotech, Inc. has a consensus price target of $5.55, signalling upside risk potential of 472.27%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $105.58 which suggests that it could grow by 1176.68%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ONCYOncolytics Biotech, Inc.3 1 0 PMNProMIS Neurosciences, Inc.2 0 0 -
Is ONCY or PMN More Risky?
Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.050, suggesting its less volatile than the S&P 500 by 105.015%.
-
Which is a Better Dividend Stock ONCY or PMN?
Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONCY or PMN?
Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than ProMIS Neurosciences, Inc. quarterly revenues of --. Oncolytics Biotech, Inc.'s net income of -$10.5M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M PMNProMIS Neurosciences, Inc.-- -- -- -$11.6M
-
Which has Higher Returns ONCY or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Oncolytics Biotech, Inc.'s net margin of -867.29%. Oncolytics Biotech, Inc.'s return on equity of -635.07% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About ONCY or XENE?
Oncolytics Biotech, Inc. has a consensus price target of $5.55, signalling upside risk potential of 472.27%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.09%. Given that Oncolytics Biotech, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ONCYOncolytics Biotech, Inc.3 1 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is ONCY or XENE More Risky?
Oncolytics Biotech, Inc. has a beta of 0.880, which suggesting that the stock is 11.965% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock ONCY or XENE?
Oncolytics Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oncolytics Biotech, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONCY or XENE?
Oncolytics Biotech, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Oncolytics Biotech, Inc.'s net income of -$10.5M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Oncolytics Biotech, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncolytics Biotech, Inc. is -- versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
